PegBio Co

PegBio Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of PegBio Co (2565.HK) as of Nov 19, 2026 is 74.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 65.17 % — a change of 14.57% (higher).

FCF Conversion

74.66 %

YoY

14.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of PegBio Co is 2025 74.66 % . FCF Conversion Rate (FCF/EBITDA) of PegBio Co was 2024 65.17 % . It decreases by 14.57% higher compared to the previous year.

The PegBio Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
56.97 CNY
Jan 1, 2023
83.84 CNY
Jan 1, 2024
65.17 CNY
Jan 1, 2025
74.66 CNY
The PegBio Co FCF Conversion history
YEARFCF ConversionYoY
74.66 %+14.57%
65.17 %-22.27%
83.84 %+47.15%
56.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

FCF Conversion Rate (FCF/EBITDA) of PegBio Co is 74.66 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of PegBio Co changed from 65.17 % to 74.66 %, representing a 14.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s PegBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PegBio Co

All Key Metrics — PegBio Co